3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
3
Pleural Effusion, Malignant
2
Pleural Effusion
2
Mesothelioma
2
Solitary Pulmonary Nodule
1
Pleural Diseases
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mediastinal Neoplasms
1
Liver Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Disease
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Cisplatin
115
Radiotherapy
83
Paclitaxel
77
Fluorouracil
61
Carboplatin
41
Drug Therapy
34
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Oxaliplatin
23
Neoadjuvant Therapy
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
17
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
15
Leucovorin
15
Nivolumab
14
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
anlotinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Squamous Cell Carcinoma
×
Thoracoscopy
×
Clear all
NCT02188615
2014-07-11
NACRFMIE
Taizhou Hospital
Phase 2
Unknown
120 enrolled